Cognitive function as an emerging treatment target for marijuana addiction

Experimental and Clinical Psychopharmacology

Volumn 18, Issue 2, 2010, Pages 109-119

  Sofuoglu, Mehmet ^a   Sugarman, Dawn E ^a   Carroll, Kathleen M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholine; Cannabis; Cholinesterase inhibitors; Cognitive function; Marijuana

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CHOLINESTERASE INHIBITOR; CYCLOSERINE; DONEPEZIL; DRONABINOL; EPTASTIGMINE; GALANTAMINE; LOFEXIDINE; PHYSOSTIGMINE; RIMONABANT; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ANOREXIA; ANXIETY DISORDER; ARTICLE; ATTENTION; BEHAVIOR THERAPY; CANNABIS ADDICTION; CHOLINERGIC NERVE CELL; COGNITIVE DEFECT; COGNITIVE REHABILITATION; DEMENTIA; DEPRESSION; DIARRHEA; DIZZINESS; HIPPOCAMPUS; HUMAN; LEARNING; LIVER TOXICITY; LONG TERM EXPOSURE; LONG TERM POTENTIATION; MEMORY; NAUSEA; NONHUMAN; PHOBIA; PREFRONTAL CORTEX; PROGNOSIS; SUICIDAL BEHAVIOR; VOMITING; WITHDRAWAL SYNDROME; WORKING MEMORY;

ANIMALS; BEHAVIOR THERAPY; CANNABINOIDS; CHOLINERGIC AGONISTS; COGNITION DISORDERS; DRUG DELIVERY SYSTEMS; HUMANS; MARIJUANA ABUSE; NEUROTRANSMITTER AGENTS; THERAPY, COMPUTER-ASSISTED;

EID: 77952815385     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/a0019295     Document Type: Article

References (157)

1. Acheson A., de Wit H. Bupropion improves attention but does not affect impulsive behavior in healthy young adults. Experimental and Clinical Psychopharmacology 2008, 16:113-123.
2. Agrawal A., Lynskey M.T., Pergadia M.L., Bucholz K.K., Heath A.C., Martin N.G., et al. Early cannabis use and DSM-IV nicotine dependence: A twin study. Addiction 2008, 103:1896-1904.
3. Aharonovich E., Brooks A.C., Nunes E.V., Hasin D.S. Cognitive deficits in marijuana users: Effects on motivational enhancement therapy plus cognitive behavioral therapy treatment outcome. Drug and Alcohol Dependence 2008, 95:279-283.
4. Aharonovich E., Hasin D.S., Brooks A.C., Liu X., Bisaga A., Nunes E.V. Cognitive deficits predict low treatment retention in cocaine dependent patients. Drug and Alcohol Dependence 2006, 81:313-322.
5. Aharonovich E., Nunes E., Hasin D. Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment. Drug and Alcohol Dependence 2003, 71:207-211.
6. Bates M.E., Pawlak A.P., Tonigan J.S., Buckman J.F. Cognitive impairment influences drinking outcome by altering therapeutic mechanisms of change. Psychology of Addictive Behavior 2006, 20:241-253.
7. Bell M., Bryson G., Greig T., Corcoran C., Wexler B.E. Neurocognitive enhancement therapy with work therapy: Effects on neuropsychological test performance. Archives of General Psychiatry 2001, 58:763-768.
8. Berlanga M.L., Olsen C.M., Chen V., Ikegami A., Herring B.E., Duvauchelle C.L., et al. Cholinergic interneurons of the nucleus accumbens and dorsal striatum are activated by the self-administration of cocaine. Neuroscience 2003, 120:1149-1156.
9. Bhattacharyya S., Morrison P.D., Fusar-Poli P., Martin-Santos R., Borgwardt S., Winton-Brown T., et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2009.
10. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database System Review 2006, 1:CD005593.
11. Block R.I., O'Leary D.S., Hichwa R.D., Augustinack J.C., Ponto L.L., Ghoneim M.M., et al. Cerebellar hypoactivity in frequent marijuana users. Neuroreport 2000, 11:749-753.
12. Bohme G.A., Laville M., Ledent C., Parmentier M., Imperato A. Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors. Neuroscience 2000, 95:5-7.
13. Bolla K.I., Brown K., Eldreth D., Tate K., Cadet J.L. Dose-related neurocognitive effects of marijuana use. Neurology 2002, 59:1337-1343.
14. Braida D., Sala M. Cannabinoid-induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats. Neuroreport 2000, 11:2025-2029.
15. Briand L.A., Gritton H., Howe W.M., Young D.A., Sarter M. Modulators in concert for cognition: Modulator interactions in the prefrontal cortex. Progress in Neurobiology 2007, 83:69-91.
16. Brown A.J. Novel cannabinoid receptors. British Journal of Pharmacology 2007, 152:567-575.
17. Budney A.J., Higgins S.T., Radonovich K.J., Novy P.L. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. Journal of Consulting and Clinical Psychology 2000, 68:1051-1061.
18. Budney A.J., Moore B.A., Rocha H.L., Higgins S.T. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. Journal of Consulting and Clinical Psychology 2006, 74:307-316.
19. Budney A.J., Roffman R., Stephens R.S., Walker D. Marijuana dependence and its treatment. Addiction Science and Clinical Practice 2007, 4:4-16.
20. Budney A.J., Vandrey R.G., Hughes J.R., Moore B.A., Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug and Alcohol Dependence 2007, 86:22-29.
21. Camicioli R., Gauthier S. Clinical trials in Parkinson's disease dementia and dementia with Lewy bodies. Canadian Journal of Neurological Sciences 2007, 34(Suppl. 1):S109-117.
22. Carroll K.M., Easton C.J., Nich C., Hunkele K.A., Neavins T.M., Sinha R., et al. The use of contingency management and motivational/skills-building therapy to treat young adults with marijuana dependence. Journal of Consulting and Clinical Psychology 2006, 74:955-966. PMCID: PMC2148500.
23. Carta G., Nava F., Gessa G.L. Inhibition of hippocampal acetylcholine release after acute and repeated Delta9-tetrahydrocannabinol in rats. Brain Research 1998, 809:1-4.
24. Chambers C.D., Garavan H., Bellgrove M.A. Insights into the neural basis of response inhibition from cognitive and clinical neuroscience. Neuroscience and Biobehavioral Reviews 2009, 33:631-646.
25. Collins D.R., Pertwee R.G., Davies S.N. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. British Journal of Pharmacology 1995, 115:869-870.
26. Colzato L.S., van den Wildenberg W.P., Hommel B. Impaired inhibitory control in recreational cocaine users. PLoS ONE 2007, 2:e1143.
27. Compton W.M., Grant B.F., Colliver J.D., Glantz M.D., Stinson F.S. Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. Journal of the American Medical Association 2004, 291:2114-2121.
28. Davies S.N., Pertwee R.G., Riedel G. Functions of cannabinoid receptors in the hippocampus. Neuropharmacology 2002, 42:993-1007.
29. D'Souza D.C., Ranganathan M., Braley G., Gueorguieva R., Zimolo Z., Cooper T., et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 2008, 33:2505-2516.
30. Degroot A., Kofalvi A., Wade M.R., Davis R.J., Rodrigues R.J., Rebola N., et al. CB1 receptor antagonism increases hippocampal acetylcholine release: Site and mechanism of action. Molecular Pharmacology 2006, 70:1236-1245.
31. Denis C., Lavie E., Fatseas M., Auriacombe M. Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database Syst Rev 2006, 3:CD005336.
32. de Wit H. Impulsivity as a determinant and consequence of drug use: A review of underlying processes. Addict Biol 2009, 14:22-31.
33. Donovan D.M., Kivlahan D.R., Walker R.D. Clinical limitations of neuropsychological testing in predicting treatment outcome among alcoholics. Alcoholism, Clinical and Experimental Research 1984, 8:470-475.
34. Egerton A., Allison C., Brett R.R., Pratt J.A. Cannabinoids and prefrontal cortical function: Insights from preclinical studies. Neuroscience and Biobehavioral Reviews 2006, 30:680-695.
35. Eldreth D.A., Matochik J.A., Cadet J.L., Bolla K.I. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimage 2004, 23:914-920.
36. ElSohly M.A., Ross S.A., Mehmedic Z., Arafat R., Yi B., Banahan B.F. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. Journal of Forensic Sciences 2000, 45:24-30.
37. Ersche K.D., Sahakian B.J. The neuropsychology of amphetamine and opiate dependence: Implications for treatment. Neuropsychology Review 2007, 17:317-336.
38. Everitt B.J., Hutcheson D.M., Ersche K.D., Pelloux Y., Dalley J.W., Robbins T.W. The orbital prefrontal cortex and drug addiction in laboratory animals and humans. Annals of the New York Academy of Sciences 2007, 1121:576-597.
39. Fals-Stewart W. Neurocognitive defects and their impact on substance abuse treatment. Journal of Addictions & Offender Counseling 1993, 13:46-57.
40. Fals-Stewart W. The effect of cognitive rehabilitation on the neuropsychological status of patients in drug abuse treatment who display neurocognitive impairment. Rehabilitation Psychology 1994, 39:75-94.
41. Fals-Stewart W., Bates M.E. The neuropsychological test performance of drug-abusing patients: An examination of latent cognitive abilities and risk factors. Experimental and Clinical Psychopharmacology 2003, 11:34-45.
42. Fals-Stewart, W., & Lam, W. K. K. (in press). Computer-assisted cignitive rehabilitation for the treatment of patients with substance use disorders: A randomized clinical trial. Experimental and Clinical Psychopharmacology.
43. Fals-Stewart W., Lucente S. The effect of cognitive rehabilitation on the neuropsychological status of patients in drug abuse treatment who display neurocognitive impairment. Rehabilitation Psychology 1994, 39:75-94.
44. Fals-Stewart W., Schafer J. The relationship between length of stay in drug-free therapeutic communities and neurocognitive functioning. Journal of Clinical Psychology 1992, 48:539-543.
45. Fals-Stewart W., Schafer J., Lucente S., Rustine T., Brown L. Neurobehavioral consequences of prolonged alcohol and substance abuse: A review of findings and treatment implications. Clinical Psychology Review 1994, 14:755-778.
46. Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer's disease. International Psychogeriatrics 2002, 14(Suppl. 1):93-126.
47. Farlow M.R. Treatment of mild cognitive impairment (MCI). Curr Alzheimer Res 2009, 6:362-367.
48. Ferdinand R.F., Sondeijker F., van der Ende J., Selten J.P., Huizink A., Verhulst F.C. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 2005, 100:612-618.
49. Fillmore M.T., Rush C.R. Impaired inhibitory control of behavior in chronic cocaine users. Drug and Alcohol Dependence 2002, 66:265-273.
50. Fried P.A., Watkinson B., Gray R. Neurocognitive consequences of marihuana-a comparison with pre-drug performance. Neurotoxicology and Teratology 2005, 27:231-239.
51. Friedman A.S., Glassman K., Terras B.A. Violent behavior as related to use of marijuana and other drugs. Journal of Addictive Diseases 2001, 20:49-72.
52. Fukudome Y., Ohno-Shosaku T., Matsui M., Omori Y., Fukaya M., Tsubokawa H., et al. Two distinct classes of muscarinic action on hippocampal inhibitory synapses: M2-mediated direct suppression and M1/M3-mediated indirect suppression through endocannabinoid signalling. European Journal of Neuroscience 2004, 19:2682-2692.
53. Galvin J.E., Cornblatt B., Newhouse P., Ancoli-Israel S., Wesnes K., Williamson D., et al. Effects of galantamine on measures of attention: Results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil. Alzheimer Disease and Associated Disorders 2008, 22:30-38.
54. Gessa G.L., Casu M.A., Carta G., Mascia M.S. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. European Journal of Pharmacology 1998, 355:119-124.
55. Gessa G.L., Mascia M.S., Casu M.A., Carta G. Inhibition of hippocampal acetylcholine release by cannabinoids: Reversal by SR 141716A. European Journal of Pharmacology 1997, 327:R1-R2.
56. Giacobini E. Cholinesterase inhibitors: New roles and therapeutic alternatives. Pharmacological Research 2004, 50:433-440.
57. Grant I., Gonzalez R., Carey C.L., Natarajan L., Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: A meta-analytic study. Journal of the International Neuropsychological Society 2003, 9:679-689.
58. Grohman K., Fals-Stewart W., Donnelly K. Improving treatment response of cognitively impaired veterans with neuropsychological rehabilitation. Brain and Cognition 2006, 60:203-204.
59. Gruber S.A., Yurgelun-Todd D.A. Neuroimaging of marijuana smokers during inhibitory processing: A pilot investigation. Brain Research. Cognitive Brain Research 2005, 23:107-118.
60. Hall W., Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009, 374:1383-1391.
61. Han C.J., Robinson J.K. Cannabinoid modulation of time estimation in the rat. Behavioral Neuroscience 2001, 115:243-246.
62. Haney M., Hart C.L., Vosburg S.K., Comer S.D., Reed S.C., Foltin R.W. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl) 2008, 197:157-168.
63. Hansen R.A., Gartlehner G., Webb A.P., Morgan L.C., Moore C.G., Jonas D.E. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis. Clin Interv Aging 2008, 3:211-225.
64. Hart C.L. Increasing treatment options for cannabis dependence: A review of potential pharmacotherapies. Drug and Alcohol Dependence 2005, 80:147-159.
65. Hart C.L., van Gorp W., Haney M., Foltin R.W., Fischman M.W. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 2001, 25:757-765.
66. Heifets B.D., Castillo P.E. Endocannabinoid signaling and long-term synaptic plasticity. Annual Review of Physiology 2009, 71:283-306.
67. Heishman S.J., Huestis M.A., Henningfield J.E., Cone E.J. Acute and residual effects of marijuana: Profiles of plasma THC levels, physiological, subjective, and performance measures. Pharmacology, Biochemistry and Behavior 1990, 37:561-565.
68. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.U., et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal 2005, 330:11.
69. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., et al. Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:1932-1936.
70. Hester R., Garavan H. Executive dysfunction in cocaine addiction: Evidence for discordant frontal, cingulate, and cerebellar activity. Journal of Neuroscience 2004, 24:11017-11022.
71. Hoffman A.F., Oz M., Yang R., Lichtman A.H., Lupica C.R. Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation. Learn Mem 2007, 14:63-74.
72. Hooker W.D., Jones R.T. Increased susceptibility to memory intrusions and the Stroop interference effect during acute marijuana intoxication. Psychopharmacology 1987, 91:20-24.
73. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews 2002, 54:161-202.
74. Huestis M.A., Gorelick D.A., Heishman S.J., Preston K.L., Nelson R.A., Moolchan E.T., et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Archives of General Psychiatry 2001, 58:322-328.
75. Jacobsen L.K., Pugh K.R., Constable R.T., Westerveld M., Mencl W.E. Functional correlates of verbal memory deficits emerging during nicotine withdrawal in abstinent adolescent cannabis users. Biological Psychiatry 2007, 61:31-40.
76. Jager G., Kahn R.S., Van Den Brink W., Van Ree J.M., Ramsey N.F. Long-term effects of frequent cannabis use on working memory and attention: An fMRI study. Psychopharmacology (Berl) 2006, 185:358-368.
77. Janero D.R., Makriyannis A. Cannabinoid receptor antagonists: Pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs 2009, 14:43-65.
78. Kadden R.M., Litt M.D., Kabela-Cormier E., Petry N.M. Abstinence rates following behavioral treatments for marijuana dependence. Addictive Behaviors 2007, 32(6):1220-1236.
79. Kalivas P.W., Volkow N.D. The neural basis of addiction: A pathology of motivation and choice. American Journal of Psychiatry 2005, 162:1403-1413.
80. Katz E.C., King S.D., Schwartz R.P., Weintraub E., Barksdale W., Robinson R., et al. Cognitive ability as a factor in engagement in drug abuse treatment. American Journal of Drug and Alcohol Abuse 2005, 31:359-369.
81. Kempel P., Lampe K., Parnefjord R., Hennig J., Kunert H.J. Auditory-evoked potentials and selective attention: Different ways of information processing in cannabis users and controls. Neuropsychobiology 2003, 48:95-101.
82. Khateb A., Ammann J., Annoni J.M., Diserens K. Cognition-enhancing effects of donepezil in traumatic brain injury. European Neurology 2005, 54:39-45.
83. Kirk J.M., de Wit H. Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users. Pharmacology, Biochemistry and Behavior 1999, 63:137-142.
84. Knudsen E.I. Fundamental components of attention. Annual Review of Neuroscience 2007, 30:57-78.
85. Le Foll B., Gorelick D.A., Goldberg S.R. The future of endocannabinoid-oriented clinical research after CB(1) antagonists. Psychopharmacology (Berl) 2009, 205:171-174.
86. Leweke M., Kampmann C., Radwan M., Dietrich D.E., Johannes S., Emrich H.M., et al. The effects of tetrahydrocannabinol on the recognition of emotionally charged words: An analysis using event-related brain potentials. Neuropsychobiology 1998, 37:104-111.
87. Li C.S., Huang C., Yan P., Bhagwagar Z., Milivojevic V., Sinha R. Neural correlates of impulse control during stop signal inhibition in cocaine-dependent men. Neuropsychopharmacology 2008, 33:1798-1806.
88. Li C.S., Milivojevic V., Kemp K., Hong K., Sinha R. Performance monitoring and stop signal inhibition in abstinent patients with cocaine dependence. Drug and Alcohol Dependence 2006, 85:205-212.
89. Lichtman A.H., Dimen K.R., Martin B.R. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl) 1995, 119:282-290.
90. Lichtman A.H., Martin B.R. Cannabinoid tolerance and dependence. Handb Exp Pharmacol 2005, 168:691-717.
91. Louis W.J., Jarrott B., Conway E.L. Sites of actions of alpha 2 agonists in the brain and periphery. American Journal of Cardiology 1988, 61:15D-17D.
92. Lucas-Meunier E., Fossier P., Baux G., Amar M. Cholinergic modulation of the cortical neuronal network. Pflugers Archiv. European Journal of Physiology 2003, 446:17-29.
93. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 2005, 168:299-325.
94. Mallet P.E., Beninger R.J. The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide. Psychopharmacology (Berl) 1998, 140:11-19.
95. Marks D.F., MacAvoy M.G. Divided attention performance in cannabis users and non-users following alcohol and cannabis separately and in combination. Psychopharmacology 1989, 99:397-401.
96. Martin G., Copeland J. The adolescent cannabis check-up: Randomized trial of a brief intervention for young cannabis users. Journal of Substance Abuse Treat 2008, 34:407-414.
97. McCambridge J., Slym R.L., Strang J. Randomized controlled trial of motivational interviewing compared with drug information and advice for early intervention among young cannabis users. Addiction 2008, 103:1809-1818.
98. McDonald J., Schleifer L., Richards J.B., de Wit H. Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 2003, 28:1356-1365.
99. McKinney D.L., Cassidy M.P., Collier L.M., Martin B.R., Wiley J.L., Selley D.E., et al. Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol. Journal of Pharmacology and Experimental Therapeutics 2008, 324:664-673.
100. McNally R.J. Mechanisms of exposure therapy: How neuroscience can improve psychological treatments for anxiety disorders. Clinical Psychology Review 2007, 27:750-759.
101. Medina K.L., Hanson K.L., Schweinsburg A.D., Cohen-Zion M., Nagel B.J., Tapert S.F. Neuropsychological functioning in adolescent marijuana users: Subtle deficits detectable after a month of abstinence. Journal of the International Neuropsychological Society 2007, 13:807-820.
102. Mesulam M.M. The cholinergic innervation of the human cerebral cortex. Progress in Brain Research 2004, 145:67-78.
103. Miller L.L., McFarland D., Cornett T.L., Brightwell D. Marijuana and memory impairment: Effect on free recall and recognition memory. Pharmacology, Biochemistry & Behavior 1977, 7:99-103.
104. Mishima K., Egashira N., Matsumoto Y., Iwasaki K., Fujiwara M. Involvement of reduced acetylcholine release in Delta9-tetrahydrocannabinol-induced impairment of spatial memory in the 8-arm radial maze. Life Sciences 2002, 72:397-407.
105. Misner D.L., Sullivan J.M. Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. Journal of Neuroscience 1999, 19:6795-6805.
106. Monti B., Contestabile A. Memory-enhancing drugs: A molecular perspective. Mini Rev Med Chem 2009, 9:769-781.
107. Brief treatments for cannabis dependence: Findings from a randomized multisite trial. Journal of Consulting and Clinical Psychology 2004, 72:455-466. MTP Research Group.
108. Nava F., Carta G., Battasi A.M., Gessa G.L. D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration. British Journal of Pharmacology 2000, 130:1201-1210.
109. Nava F., Carta G., Colombo G., Gessa G.L. Effects of chronic Delta(9)-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze. Neuropharmacology 2001, 41:392-399.
110. Nordstrom B.R., Levin F.R. Treatment of cannabis use disorders: A review of the literature. American Journal On Addictions 2007, 16:331-342.
111. O'Leary M.R., Donovan D.M., Chaney E.F., Walker R.D. Cognitive impairment and treatment outcome with alcoholics: Preliminary findings. Journal of Clinical Psychiatry 1979, 40:397-398.
112. Ochoa E.L., Clark E. Galantamine may improve attention and speech in schizophrenia. Hum Psychopharmacol 2006, 21:127-128.
113. Ohno-Shosaku T., Matsui M., Fukudome Y., Shosaku J., Tsubokawa H., Taketo M.M., et al. Postsynaptic M1 and M3 receptors are responsible for the muscarinic enhancement of retrograde endocannabinoid signalling in the hippocampus. European Journal of Neuroscience 2003, 18:109-116.
114. Olmstead T.A., Sindelar J.L., Easton C.J., Carroll K.M. The cost-effectiveness of four treatments for marijuana dependence. Addiction 2007, 102:1443-1453.
115. Marijuana: The greatest cause of illegal drug abuse 2008, ONDCP, Executive Office of the President, Washington, DC.
116. Penetar D.M., Kouri E.M., Gross M.M., McCarthy E.M., Rhee C.K., Peters E.N., et al. Transdermal nicotine alters some of marihuana's effects in male and female volunteers. Drug and Alcohol Dependence 2005, 79:211-223.
117. Pijlman F.T., Rigter S.M., Hoek J., Goldschmidt H.M., Niesink R.J. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict Biol 2005, 10:171-180.
118. Pope H.G., Gruber A.J., Hudson J.I., Cohane G., Huestis M.A., Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: What is the nature of the association?. Drug and Alcohol Dependence 2003, 69:303-310.
119. Pope H.G., Gruber A.J., Hudson J.I., Huestis M.A., Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Archives of General Psychiatry 2001, 58:909-915.
120. Pope H.G., Gruber A.J., Yurgelun-Todd D. The residual neuropsychological effects of cannabis: The current status of research. Drug & Alcohol Dependence 1995, 38:25-34.
121. Pope H.G., Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. Journal of the American Medical Association 1996, 275:521-527.
122. Porrino L.J., Smith H.R., Nader M.A., Beveridge T.J. The effects of cocaine: A shifting target over the course of addiction. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 31:1593-1600.
123. Posner M.I., Rothbart M.K. Research on attention networks as a model for the integration of psychological science. Annual Review of Psychology 2007, 58:1-23.
124. Potter D.J., Clark P., Brown M.B. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: Implications for psychoactivity and pharmacology. Journal of Forensic Sciences 2008, 53:90-94.
125. Ramaekers J.G., Kauert G., Theunissen E.L., Toennes S.W., Moeller M.R. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. Journal of Psychopharmacology 2009, 23:266-277.
126. Ramaekers J.G., Kauert G., van Ruitenbeek P., Theunissen E.L., Schneider E., Moeller M.R. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 2006, 31:2296-2303.
127. Reibaud M., Obinu M.C., Ledent C., Parmentier M., Bohme G.A., Imperato A. Enhancement of memory in cannabinoid CB1 receptor knock-out mice. European Journal of Pharmacology 1999, 379:R1-2.
128. Ressler K.J., Rothbaum B.O., Tannenbaum L., Anderson P., Graap K., Zimand E., et al. Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Archives of General Psychiatry 2004, 61:1136-1144.
129. Ritchie C.W., Ames D., Clayton T., Lai R. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. American Journal of Geriatric Psychiatry 2004, 12:358-369.
130. Santa Ana E.J., Rounsaville B.J., Frankforter T.L., Nich C., Babuscio T., Poling J., et al. D-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: A pilot investigation. Drug and Alcohol Dependence 2009, 104:220-227.
131. Sewell R.A., Poling J., Sofuoglu M. The effect of cannabis compared with alcohol on driving. American Journal on Addictions 2009, 18:185-193.
132. Smythies J. Section I. The cholinergic system. International Review of Neurobiology 2005, 64:1-122.
133. Sofuoglu M. Cognitive Enhancement as a Pharmacotherapy Target for Stimulant Addiction. Addiction 2010, 105:38-48.
134. Sofuoglu M., Mooney M. Cholinergic functioning in stimulant addiction: Implications for medications development. CNS Drugs 2009, 23:939-952.
135. Sofuoglu, M., Poling, J., Sewell, A., Waters, A., & Carroll, K. (2009). Galantamine effects on cognitive function in abstinent cocaine users. Manuscript submitted for publication.
136. Solinas M., Scherma M., Tanda G., Wertheim C.E., Fratta W., Goldberg S.R. Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide. Journal of Pharmacology and Experimental Therapeutics 2007, 321:1127-1134.
137. Solowij N. Do cognitive impairments recover following cessation of cannabis use?. Life Sciences 1995, 56:2119-2126.
138. Solowij N., Battisti R. The chronic effects of cannabis on memory in humans: A review. Current Drug Abuse Reviews 2008, 1:81-98.
139. Solowij N., Michie P.T., Fox A.M. Differential impairments of selective attention due to frequency and duration of cannabis use. Biological Psychiatry 1995, 37:731-739.
140. Solowij N., Stephens R.S., Roffman R.A., Babor T., Kadden R., Miller M., et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. [comment] [erratum appears in JAMA 2002, 287, 1651]. Journal of the American Medical Association 2002, 287:1123-1131.
141. Stephens R.S., Babor T.F., Kadden R., Miller M. The Marijuana Treatment Project: Rationale, design, and participant characteristics. Addiction 2002, 97:109-124. M. T. P. Research Group.
142. Stephens R.S., Roffman R.A., Curtin L. Comparison of extended versus brief treatments for marijuana use. Journal of Consulting and Clinical Psychology 2000, 68:898-908.
143. Stephens R.S., Roffman R.A., Simpson E.E. Treating adult marijuana dependence: A test of the relapse prevention model. Journal of Consulting and Clinical Psychology 1994, 62:92-99.
144. Tarditi A., Caricasole A., Terstappen G. Therapeutic targets for Alzheimer's disease. Expert Opin Ther Targets 2009, 13:551-567.
145. Terranova J.P., Michaud J.C., Le Fur G., Soubrie P. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: Reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Naunyn-Schmiedebergs Archives of Pharmacology 1995, 352:576-579.
146. Results from the 2008 national survey on drug use and health: National findings (NSDUH Series H-36, HHS Publication No. SMA 09-4434) 2008, U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Rockville, MD.
147. Valjent E., Mitchell J.M., Besson M.J., Caboche J., Maldonado R. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. British Journal of Pharmacology 2002, 135:564-578.
148. Vann R.E., Warner J.A., Bushell K., Huffman J.W., Martin B.R., Wiley J.L. Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice. European Journal of Pharmacology 2009, 615:102-107.
149. Varvel S.A., Hamm R.J., Martin B.R., Lichtman A.H. Differential effects of delta 9-THC on spatial reference and working memory in mice. Psychopharmacology (Berl) 2001, 157:142-150.
150. Vocci F.J. Cognitive remediation in the treatment of stimulant abuse disorders: A research agenda. Experimental and Clinical Psychopharmacology 2008, 16:484-497.
151. Wagner F.A., Anthony J.C. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology 2002, 26:479-488.
152. Walker D.D., Roffman R.A., Stephens R.S., Wakana K., Berghuis J., Kim W. Motivational enhancement therapy for adolescent marijuana users: A preliminary randomized controlled trial. Journal of Consulting and Clinical Psychology 2006, 74:628-632.
153. Wilhelm S., Buhlmann U., Tolin D.F., Meunier S.A., Pearlson G.D., Reese H.E., et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. American Journal of Psychiatry 2008, 165:335-341. quiz 409.
154. Winsauer P.J., Lambert P., Moerschbaecher J.M. Cannabinoid ligands and their effects on learning and performance in rhesus monkeys. Behavioural Pharmacology 1999, 10:497-511.
155. Yucel M., Solowij N., Respondek C., Whittle S., Fornito A., Pantelis C., et al. Regional brain abnormalities associated with long-term heavy cannabis use. Archives of General Psychiatry 2008, 65:694-701.
156. Zimmerberg B., Glick S.D., Jarvik M.E. Impairment of recent memory by marihuana and THC in rhesus monkeys. Nature 1971, 233:343-345.
157. Zuardi A.W. Cannabidiol: From an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008, 30:271-280.